A Link between mir-100 and FRAP1/mTOR in Clear Cell Ovarian Cancer
Ankur K. Nagaraja(Novartis (Switzerland)), Martin M. Matzuk(Baylor College of Medicine), Preethi H. Gunaratne(Baylor College of Medicine), Jeffrey G. Reid(Baylor College of Medicine), Matthew L. Anderson(Institute for Molecular Medicine), Zhifeng Yu(Hangzhou Normal University), Hiroaki Itamochi(Tottori University), Shannon M. Hawkins(Indiana University School of Medicine), Naoto T. Ueno(Breast Cancer Care), Emuejevoke Olokpa(Baylor College of Medicine), Huifeng Zhu(Baylor College of Medicine), Chad J. Creighton(Baylor College of Medicine)
Cited by 232
Related Papers
UALCAN: A Portal for Facilitating Tumor Subgroup Gene Expression and Survival Analyses
|Neoplasia|2017|6.5k
UALCAN: An update to the integrated cancer data analysis platform
|Neoplasia|2022|2.5k
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
|New England Journal of Medicine|2022|2.5k
Clinical Whole-Exome Sequencing for the Diagnosis of Mendelian Disorders
|New England Journal of Medicine|2013|2k